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Abstract: Mutations in the mitochondrial aminoacyl-tRNA synthetases (mtaaRSs) can cause
profound clinical presentations, and have manifested as diseases with very selective tissue
specificity. To date most of the mtaaRS mutations could be phenotypically recognized, such that
clinicians could identify the affected mtaaRS from the symptoms alone. Among the recently
reported pathogenic variants are point mutations in FARS2 gene, encoding the human
mitochondrial PheRS. Patient symptoms range from spastic paraplegia to fatal infantile Alpers
encephalopathy. How clinical manifestations of these mutations relate to the changes in
three-dimensional structures and kinetic characteristics remains unclear, although impaired
aminoacylation has been proposed as possible etiology of diseases. Here, we report four crystal
structures of HsmtPheRS mutants, and extensive MD simulations for wild-type and nine mutants to
reveal the structural changes on dynamic trajectories of HsmtPheRS. Using steady-state kinetic
measurements of phenylalanine activation and tRNAPhe aminoacylation, we gained insight into the
structural and kinetic effects of mitochondrial disease-related mutations in FARS2 gene.
Keywords: mitochondrial diseases; mitochondrial PheRS; mutants; X-ray structures; molecular
dynamic simulations; kinetic experiments
Introduction
Mitochondria are vital organelles that are present in
all nucleated mammalian cells and possess their own
genome and biosynthetic machinery to produce both
RNAs and proteins. Of the 1500 proteins that com-
prise a functional mitochondrion, 99% of these are
Abbreviations: aa, amino acids; ABD, anticodon-binding domain; CAM, catalytic module; 3DN, aa numbering as in 3D structure;
HsmtPheRS, human mitochondrial phenylalanyl-tRNA synthetase; MD, molecular dynamic; WT, wild type.
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nuclear encoded, synthesized on cytosolic ribosomes
and imported into the mitochondrial matrix. Amongst
these are the mitochondrial mtaaRSs, which are
key components in protein biosynthesis. Abnormali-
ties in mtaaRSs are an increasingly recognized cause
of human mitochondrial disease with profound clini-
cal presentations.1 Loss of quality control in mitochon-
drial protein translation is expected to reduce
oxidative phosphorylation capacity leading to ATP
deficiency in all tissues. In the increasing number of
patients reported thus far, the pattern of which tissue
is affected is almost always associated with a particu-
lar mtaaRS, such that clinicians can often identify the
affected mtaaRS from the symptoms alone.1,2 Patho-
genic variants have been described in genes encoding
12 of the 19 mtaaRSs and are associated with a variety
of clinical presentations including leukoencephalop-
athy with brain stem and spinal cord involvement and
lactate elevation (LBSL, MIM 611105) caused by var-
iants in DARS2, pontocerebellar atrophy type 6 (MIM
611523) caused by variants in RARS2, and a fatal
infantile cardiomyopathy (MIM 614096) caused by
variants in AARS2, among others.1,2
The overall prevalence of defects in mitochon-
drial aaRS2 gene is 1% (7/800) among observed
800 patients, who are suspected of having mitochon-
drial disorders.3 It is important to note that among
them 57% (four of seven) of positive findings are
in the FARS2 gene.3 Pathogenic variants in
FARS2 encoding the human mitochondrial PheRS
(HsmtPheRS) have been associated with phenotypes
ranging from spastic paraplegia to fatal infantile
Alpers encephalopathy.4–7 How clinical manifesta-
tion and disease phenotypes of individual mutations
in HsmtPheRS, relate to the changes in their
3D-structures and enzymatic activities has remained
unclear, although impaired aminoacylation activity
of the aaRSs has been generally proposed as a
potential etiology of these diseases.
Correct charging of tRNAs with their cognate
amino acid (aa), is a crucial quality control step in
protein synthesis. The covalent linking of the correct
aa to the relevant tRNA is accomplished by the
aaRSs through a two-step aminoacylation reaction.8
Before a chemical reaction will start, the aaRS
recognizes and binds both the cognate aa and ATP
in their specific binding pockets. In the first step of
the reaction, the amino acid is activated by ATP,
forming the first intermediate Phe-AMP. In the
second step, the aa moiety is transferred to the
3’-terminal ribose of the cognate tRNA, generating
the final aminoacyl-tRNA, and releasing AMP.8
Eukaryotic cells harbor two different types of
phenylalanyl-tRNA synthetase (PheRS): the hetero-
tetrameric cytosolic and monomeric mitochondrial
forms.9–12 The mature HsmtPheRS homolog is a
single-chain enzyme comprising 415 amino acids
and crystal structures of this enzyme have now been
determined for both the native form and in com-
plexes with various ligands.13–15 The HsmtPheRS is
composed of three major structural blocks: the
N-terminal region, the CAM, and the ABD10 [Fig.
1(A)]. Conservation of the topology of the binding
site cavity is critical for correct aminoacylation. The
bottom surface of the pocket is covered by invariant
glycines, thus providing the space required for the
phenylalanine (Phe) and ATP moieties10,16 [Fig.
Figure 1. (A) The overall structure of the HsmtPheRS enzyme
complexed with PheOH-AMP is presented. The N-terminal
region (residues 1–47) depicted in dark blue, the catalytic
domain (residues 48–289) in green, and the C-terminal
domain (residues 323–415) in red. The ligand (PheOH-AMP)
is shown in ribbon representation (yellow). (B) The unbiased
(Fobs – Fcalc) electron density map of phenylalanyl-adenylate
analog (Phe-AMP) calculated with the phases derived from
the nearly complete model of HsmtPheRS and contoured at
2.0r. The protein residues participating in direct and
water-mediated contacts with PheOH-AMP are shown. Water
molecules are marked by red spheres. The anchoring of the
a-NH13 group of PheOH-AMP is achieved by direct hydrogen
bonding between the Og atom of Sera121, and the well-
ordered water molecule X9 observed in almost all PheRS
complexes. The X9 molecule, in turn, is located at an H-
bonding distance from the Og of Thr120, the Ne2 of Gln157,
and the Oe1 of Glu159.
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1(B)]. One wall is made up entirely of residues that
participate in the formation of hydrogen bonds (HB)
with the Phe substrate (via amine and carboxyl
functional groups) and transition state intermedi-
ates: Glu159, Ser121, His119, and Gln157.
Specific recognition of the Phe is achieved by
interactions where the substrate phenyl ring and
two neighboring phenyl rings of Phe232 and Phe234
make “edge-to-face” contacts17 [Fig. 1(B)]. The
appearance of the Phe substrate in such an environ-
ment doubles the attractive potential energy of
interaction of a single “edge-to-face” aromatic-aro-
matic interaction and thus makes the Phe-PheRS
recognition highly specific and very favorable ener-
getically. The anchoring of the Phe substrate amino
group is achieved by its interactions with Ser121,
His119, and via the well-ordered water molecule
with Gln157 and Glu159.
The crystal structure of HsmtPheRS-tRNAPhe
complex, biochemical and small-angle X-ray scatter-
ing data indicate that the formation of the catalyti-
cally active complex with tRNAPhe in human
mitochondria requires a significant rearrangement
of the ABD.13,18,19 To bind tRNAPhe correctly, the
ABD must undergo a 1608 hinge-type rotation
upon binding (Fig. 2). Such global repositioning of
the domains is tRNA modulated and governed by
long range electrostatic interactions.20,21 Two basic
conformations for HsmtPheRS, have revealed
themselves: a “closed” inactive unbound state and
an “open” active state upon tRNA binding.19 A tran-
sition, however, between two basic conformations,
happens through the various intermediate (probably
short-live) conformations.
To explore the effects of mutations on the func-
tional activity of HsmtPheRS in vitro, we performed
steady-state kinetic measurements for both the Phe
activation reactions and tRNAPhe aminoacylation of
WT and mutant enzymes. To gain an insight into
the problem we solved the crystal structures of four
HsmtPheRS mutants. We also ran extensive MD
simulations to reveal the structural changes on
the dynamic trajectories of HsmtPheRS, caused by
reported point mutations.
Results
Kinetic study of functional activities of
HsmtPheRS mutants
Three of the nine HsmtPheRS variants (Supporting
Information Table S1) that we analysed demonstrated
modest changes in the catalytic efficiency of charging
tRNAPhe (summarized in Table I). The Pro49Ala and
Arg387Gln mutations led to a 1.2- to 1.3-fold decrease
in the kcat/Km value due to a reduced kcat. The
Thr210Met replacement increased the catalytic effi-
ciency of tRNAPhe charging by 1.4-fold due to a lower
Km value for tRNA
Phe. Mutations of residues within
different structural domains, namely Asp289Tyr and
Arg383Cys, halved the catalytic efficiency. In the case
of Asp289Tyr, the reduced kcat/Km resulted from a
decreased kcat; whilst for Arg383Cys, it was due to a
combination of increased Km and decreased kcat (Table
I). Combination of increased Km value for Phe and a
decreased kcat caused even more significant effects in
Figure 2. Transitions from the active “open” (A) to inactive “closed” (B) conformations of HsmtPheRS upon complex formation
with tRNAPhe are shown with the tRNAPhe molecule depicted by “worm” representation.12,18 PDB ID of the HsmtPheRS
complexed with tRNAPhe is 3TUP.
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the His99Asp and Arg117Gly mutants where a 40- to
50-fold reduction in the kcat/Km value was recorded.
The effect was even stronger in two other HsmtPheRS
variants, namely His123Pro and Gly273Ser, which
demonstrated negligible ability to charge tRNAPhe.
Only by performing the kinetic measurements at very
high concentrations of the mutant enzymes, could we
estimate their catalytic efficiencies, which were at
least 3100-fold and 4000-fold lower than that of the
wild-type enzyme.
Several mutants were tested further in vitro for
functionality in Phe activation (Fig. 3, Table II). The
wild-type HsmtPheRS and the Pro49Ala mutant
both stimulate Phe-dependent ATP hydrolysis with
nearly identical specific activities. While an approxi-
mately twofold reduction in the ATP consumption
rate was seen in the His99Asp mutant, this dropped
to a 20-fold reduction in the Arg117Gly, Gly273Ser,
and His123Pro mutants. Notably, the effects on the
HsmtPheRS activity in Phe activation in the
His99Asp, His123Pro and Gly273Ser mutants did not
correlate with their efficiency of tRNAPhe aminoacyla-
tion (Tables I and II). All three of these mutations
were impaired the aa activation (Fig. 3) to a lesser
extent than in the transfer of the amino acid group to
the tRNA. The Arg117Gly and His123Pro mutations
have comparable effects on the HsmtPheRS activity at
both steps of the aminoacylation reaction.
Crystal structures
To determine whether mutations triggered confor-
mational changes in HsmtPheRS, we cloned all the
mutant sequences, expressed and purified the
recombinant proteins without His-tags in prepara-
tion for crystallization studies using conditions anal-
ogous to those used for WT HsmtPheRS.22 Only four
Table I. Kinetic Parameters of tRNAPhe Aminoacylation by HsmtPheRS Mutants
HsmtPheRS Substrate Km (mM) kcat (min
21) kcat/Km (min
21 mM21) kcat/Km (relative)
Wild-type tRNAPhe 1.26 0.2 11.56 1.2 9.6 1
Wild-type Phe 2.46 0.4 11.56 1.5 4.8 1
P49A tRNAPhe 1.16 0.2 8.36 0.8 7.5 0.78
H99D Phe 5.66 0.8 0.726 0.14 0.13 0.027
R117G Phe 126 3 1.26 0.13 0.10 0.021
H123P tRNAPhe 0.00032a
T210M tRNAPhe 0.366 0.04 4.86 0.4 13.3 1.4
G273S tRNAPhe 0.00025a
D289Y tRNAPhe 1.06 0.18 5.06 0.5 5.0 0.52
R383C tRNAPhe 2.16 0.3 8.76 0.7 4.1 0.43
R387Q tRNAPhe 1.26 0.1 116 1.2 8.3 0.86
a kcat/Km value was estimated from the initial rate of aminoacylation reaction normalized to the enzyme concentration (1.5
lM for mutant; 0.15 lM for the wild-type).
Figure 3. Phenylalanine activation by wild-type and mutant forms of HsmtPheRS. The time courses of formation of Phe-
adenylate and AMP (produced due to hydrolysis of the adenylate) was analyzed by TLC. The reaction was performed with 20
lM [a-32P]ATP, 9 mM MgCl2, 150 nM WT or mutant PheRSs, 1 mM phenylalanine, and 20 U/mL of inorganic pyrophosphatase.
These are shown in (A) wild-type HsmtPheRS; (B) mutant Pro49Ala; (C) mutant His99Asp; (D) mutant Arg117Gly; (E) mutant
His123Pro; and (F) mutant Gly273Ser.
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mutants out of nine generated crystals, which dif-
fracted to 1.87 A˚, 1.89 A˚, 2.05 A˚, and 1.46 A˚ resolu-
tion for Pro49Ala (PDB ID 5MGH), Thr210Met
(PDB ID 5MGU), Asp289Tyr (PDB ID 5MGV), and
Arg383Cis (PDB ID 5MGW), respectively (Table III).
The crystal structures of these four mutants resem-
bled each other in the overall molecular structure and
all of them are closely related to the three-
dimensional structure of WT HsmtPheRS. Upon
superimposition of the mutant crystal structures onto
that of WT HsmtPheRS, they display the following
values of r.m.s.d.: 0.256 A˚ over 347 Ca atoms for
Pro49Ala; 0.262 A˚ over 368 Ca atoms for Thr210Met;
0.194 A˚ over 364 Ca atoms for Asp289Tyr; and 0.442
A˚ over 345 Ca atoms for Arg383Cys. The failure to
crystallize Arg117Gly, Gly273Ser, His99Asp, and
His123Pro mutants may be related to the significant
conformational changes that their 3D structures
undergo. There is a straightforward interpretation of
the results as they immediately relate to the succes-
sive snapshots of MD simulations carried out for each
of the mutants. Rearrangements in the topology of the
molecule prevent formation of intermolecular con-
tacts, required for crystallization and the availability
of the long range order in the crystals. For mutant
Arg387Glu we could see only microcrystals, and failed
to get crystals suitable for X-ray data collection.
Mutant Asp289Tyr
Patient 5M (Supporting Information Table S1) is
homozygous for Asp289Tyr in the FARS2 gene
encoding HsmtPheRS. Patient 5M harbored a partial
genomic deletion and a highly conserved Asp325Tyr
missense variant (the difference in aa numbering is
236) that caused early-onset epilepsy and an iso-
lated complex IV deficiency in muscle.6 Within
HsmtPheRS, Asp289 is located at the interface of
CAM and ABD. The mutated Asp289Tyr located at a
distance from the synthetic active site and the con-
tact area with cognate tRNA. The mutant demon-
strates, however, a twofold reduction in the catalytic
efficiency, due to a decreased kcat value (Table I).
Whilst no initial evidence suggests that this muta-
tion is responsible for the observed reduction of the
catalytic constant, we crystallized the mutated
HsmtPheRS in the complex with Phe and ATP, as
previously described13,22 to identify its effect on 3D
structure. The crystals diffracted to 2.0 A˚ resolution
and belong to the space group P212121, with unit cell
parameters of a5 54.9 A˚, b5 90.0 A˚, c5 96.0 A˚ (see
Materials and Methods). The final atomic model
Table II. Specific Activities of HsmtPheRS Mutants in
the Phe Activation Reaction
HsmtPheRS
Initial velocity
(mM/min)
Initial velocity
(relative)
WT 0.546 0.05 1
P49A 0.666 0.05 1.2
H99D 0.216 0.03 0.39
R117G 0.026 0.002 0.042
H123P 0.026 0.002 0.043
G273S 0.046 0.003 0.06
The initial velocities of the activation reaction were deter-
mined by ATP consumption assay at identical concentra-
tions of WT and mutant enzymes (0.8 mM).
Table III. Data Collection and Refinement of HsmtPheRS Mutants
Pro49Ala Thr210Met Asp289Tyr Arg383Cys
Resolution range (A˚) 47.9–1.87 (1.94–1.87) 46.66–1.89 (1.96–1.89) 50.05–2.05 (2.08–2.05) 45.9–1.46 (1.512–1.46)
Space group P 21 21 21 P 21 21 21 P 212121 P 21 21 21
Cell dimensions a, b, c (A˚) 55.04, 89.35, 97.23 54.54, 90.13, 97.45 54.77, 90.37, 95.17 53.35, 90.12, 99.08
a, b, c (8) 90, 90, 90 90, 90, 90 90,90,90 90, 90, 90
Unique reflections 40,252 (3917) 38,365 (3749) 28,291 (1373) 83,388 (8212)
Completeness (%) 100 98 93.2 100
Mean I/sigma (I) 25.2 22.14 25.22 33.2
Wilson B-factor (A˚2) 35.84 37.27 25.15 21.09
R-merge 7.2 6.8 7.0 5.1
Reflections used
in refinement
40,241 (3913) 38,356 (3746) 26,918 (1373) 83,373 (8208)
Reflections used for R-free 2003 (204) 1999 (195) 679 (40) 2000 (197)
R-work 0.1976 (0.3070) 0.2024 (0.3579) 0.2089 (0.2574) 0.1851 (0.3112)
R-free 0.2299 (0.3436) 0.2415 (0.4322) 0.2460 (0.3061) 0.2050 (0.3326)
No. nonhydrogen atoms 3622 3611 3607 3887
Water molecules 259 235 249 522
Protein residues 405 407 405 406
RMS (bonds) (A˚) 0.007 0.007 0.007 0.006
RMS (angles) (8) 0.91 1.00 1.2 0.82
Ramachandran favored (%) 96 95 95 97
Ramachandran allowed (%) 3.5 4.4 3.8 3.0
Ramachandran outliers (%) 0.99 0.49 1.1 0
Average B-factor 42.67 42.51 46.5 28.25
Macromolecules 42.36 42.21 39.8 26.93
Solvent 46.71 46.77 48.8 36.75
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includes 405 aa residues and 250 water molecules
(Table III). HsmtPheRS superimposed onto the WT
HsmtPheRS with r.m.s.d. 0.24 A˚ over 400 Ca atoms.
The X-ray data revealed a prominent structural dis-
tinction between the mutant HsmtPheRS and the
WT enzyme in the appearance of the edge-to-face
interactions between pair of Phe245 and His246
from the one side and Tyr289 from the other [Fig.
4(A)]. Thus, a new strong interaction between mod-
ules CAM and ABD is added to the mutated variant.
In order to uncover the reason of the activity
reduction, we performed molecular dynamic
(MD) simulations both for the WT HsmtPheRS and
Asp289Tyr mutant. The initial set of coordinates for
the two molecules corresponded to the open state of
HsmtPheRS, as experimentally observed in the com-
plex with cognate tRNAPhe.13 Simulations for WT
and mutant were performed for 50 ns (see Materials
and Methods) and revealed that the WT enzyme
generates three major clusters of inter-domain con-
tacts. These are salt bridges between ABD and CAM
that are generated upon transitions from an open
conformation to a closed one. The first contact is
formed between Arg302 and Glu358 that belong to
CAM and ABD, respectively. This bridge stabilizes
open conformations upon formation of the complex
with tRNA, and remains intact during almost half of
the total MD simulations period (20 ns). Subse-
quently, the Arg302 switches from Glu358 to
Asp355, forming the next salt bridge in the cascade
of contacts. After 40 ns the ABD moves along its
trajectory towards the closed conformation by break-
ing previous contacts with Arg302 and generating
new ones. The Asp289Tyr mutant displayed substan-
tial differences in dynamic behavior and mechanical
trajectory [Fig. 4(B)]. The conclusion from the MD
simulation is that the transition from the open
“active” conformation to the closed “inactive” one
happens almost approximately eight times faster
(6 ns) in the Asp289Tyr mutant. This led us to a
remarkable finding: statistically the mutated
enzyme spends longer time in the closed inactive
state, thereby reducing the potential for aminoacyla-
tion activity of HsmtPheRS, consistent with the
activity measurements. Thus, an in silico MD
approach appears to be very useful in revealing
functional roles of the mutations whose detrimental
effects on the catalytic efficiency are otherwise diffi-
cult to describe in terms of structure and function.
Mutant Arg117Gly
This was one of two heterozygous variants,
c.457A>G (p.Arg153Gly; in 3DN is Arg117Gly) and
c.925G>A (p.Gly309Ser; in 3DN is Gly273Ser) iden-
tified in the human FARS2 gene (NM_006567.3) of
Patient 1F (Supporting Information Table S1), both
were predicted to be deleterious by SIFT and Poly-
Phen2.3 This baby girl was 5 months old at the time
of diagnosis, presenting with poor growth, persistent
lactic acidosis with ketosis.
The residue Arg117 is located in the catalytic
core of HsmtPheRS where its guanidinium group
makes an internal salt bridge with Asp140 (in the
strand) and HB with His123 (within the same helix).
It constitutes a principal structure-forming contact
of the CAM topology by holding together and cor-
rectly spacing the flanking helices and strands.
Mutation of Arg to Gly will disturb the salt bridge
between Asp140 and Arg117, thereby triggering sig-
nificant changes in the CAM conformation. More-
over, appearance of glycine in the Leu116-Thr120
Figure 4. (A) Superimposition of the crystal structure of WT
HsmtPheRS (blue) on to the mutant Asp289Tyr structure
(burgundy) at the intersubunit interface. The perfect alignment
of 3D-structures is clearly seen. Electrostatic interaction
between His246 and Asp289 is substituted in this area for
edge-to-face interactions between Phe281 and His246 from
one side and Tyr289 from the other side. (B) Snapshots of
global molecular dynamic simulations performed for the WT
and Asp289Tyr mutant forms of HsmtPheRS (blue and
burgundy, respectively) stopped at 22 ns on the pathway
trajectory. Upon repositioning of the ABD from “closed” to an
“open” state, WT molecule and Asp289Tyr mutant are
passing through a number of similar intermediate states
(mutation on the outer surface of the enzyme). Due to slowing
down of ABD relocation in mutant, the WT and Asp289Tyr
will go through similar conformations, but at different
moments of time.
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loop involved in the Phe-AMP intermediate forma-
tion, may lead to a reduction in the enzyme activity
due to flexibility of the loop. Even after 6 ns of MD
simulation, the Phe234, which together with the
Phe substrate and Phe232 forms an edge-to-phase
recognition triplet, escapes its position in the
mutant and moves towards Trp125 [Fig. 5(A)]. The
trajectory of Trp125 motion is very long, generating
at the end a new edge-to-phase interaction with
Phe234. This rearrangement halves the binding
energy of Phe compared to the WT HsmtPheRS
(missing interaction between substrate Phe and
Phe234) and leads to a substantial reduction in Phe
activation and aminoacylation activity (Tables I and
II). The steady-state aminoacylation kinetics of the
Arg117Gly mutant showed a 50-fold reduction in
the kcat/Km value as a result of an increased Km
value for Phe and a decreased kcat in comparison
with WT enzyme (see Table I). A 24-fold reduction in
the rate of ATP consumption caused by the mutation
was also observed (Table II).
Mutant Gly273Ser
Patient 1F (Supporting Information Table S1) is het-
erozygous for Arg153Gly (3DN is Arg117Gly) and
p.Gly309Ser (Gly273Ser in 3DN; p.Arg117Gly is
described above).3 Gly273 residue belongs to the b-
strand Asp270-Gly279, one of the shape-generating
elements of CAM. The glycine-lined strand contacts
the reaction intermediate Phe-AMP23 and the emer-
gence of serine instead of glycine will result in steric
clashes between the side chains of serine and
Met258 (2 A˚). This in turn will lead to reorganiza-
tion of the hydrophobic cluster in which Met258
holds the central position. MD simulation of the
mutant reveals that Ser273 causes formation of a
new very stable HB with Gln124 (2.8–3.3 A˚), which
holds up 95% of the whole cycle of MD trajectory.
This contrasts with the WT HsmtPheRS, where this
contact is 9 to 10 A˚.
Anchoring the amino group of the Phe-substrate
is achieved by its interactions with Ser121, and
His119 via direct or water-mediated contacts.13–15
The analysis of MD snapshots in the Gly273Ser
mutant demonstrates loss of contacts between resi-
dues Ser121 and Glu159, and the amino group of
the Phe substrate. The latter moves by 5 to 6 A˚
away from its original position thereby, rendering
impossible the activation process and subsequent
aminoacylation (Fig. 3). Moreover, within 7 ns of
MD trajectory the canonical “edge-to-face” aromatic
interactions were lost and there was evidence that
the binding of the Phe substrate was also lost [Fig.
5(B)]. The kinetic experiments showed that mutant
is not charging tRNAPhe at the same concentrations
as WT HsmtPheRS (Table I). Activation and aminoa-
cylation activity of this Gly273Ser mutant (Tables I
and II) could only be detected at very high enzyme
concentrations.
Mutant His123Pro
Patient 3F is a 17-year-old girl (Supporting Informa-
tion Table S1) harboring a p.His159Pro (3DN is
His123Pro) change from the wild-type human
FARS2 gene (NM_006567.3). She presented with
developmental delay, encephalopathy, elevated CSF
lactate, and abnormal respiratory enzymes, consis-
tent with the clinical features reported for FARS2
defects. Two compound heterozygous variants,
His123Pro (from the mother) and Arg383Cys (from
the father) were identified both of which were pre-
dicted to be deleterious by SIFT and PolyPhen2.3
The complex of HsmtPheRS with tRNAPhe13
suggests that the His to Pro substitution leads to
Figure 5. Structural, dynamic and functional characterization of the Arg117Gly, Gly273Ser, and His99Asp mutants of
HsmtPheRS. (A) The diagram depicts the rearrangement of the aa residues within the active site. After 24 ns of MD simulation
the Phe234 had migrated from its standard position toward Trp125, thereby disrupting the aromatic triad forming a “network”
of edge-to-face interactions. The Phe substrate is colored light green; (B) the active site Phe bound is colored forest green. The
distance between the amino group of the ligand and Ser121 after 18 ns of MD simulation is depicted by a dashed line. Phe232
and Phe234 that provide specific recognition of Phe substrate are colored burgundy; (C) depicted is the appearance of HB
between Ser101 and Asp99 on the MD simulation trajectory. As can be seen on the snapshots of MD simulations, the position
of the Phe substrate is slightly altered.
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considerable reorganization of the structure. First,
the HB between Arg117 and His123 will be dis-
rupted; second, the presence of the His123Pro muta-
tion will break the a-helical structure (His119-
Ala130). Since the a-helical residues make direct
contact with the Phe-AMP, it is unsurprising that
this mutation leads to a dramatic reduction in the
enzymatic activity (Table I). Our data confirm that
the His123Pro mutant has lost the ability to cata-
lyze Phe-tRNAPhe production at concentrations that
give detectable activity by WT HsmtPheRS. We
estimated its catalytic efficiency to be 3100-fold
lower than that of the wild type enzyme (Table I).
All crystallization trials for the mutant failed, as a
result of the significant changes in the folding
capacity of CAM.
Mutant Pro49Ala
Patient 2F (Supporting Information Table S1), a
16-year-old girl, is heterozygous for two variants in
FARS2 (NM_006567.3), c.253C>G (Pro49Ala), and
c.403C>G (His99Asp), both predicted to be deleterious
by SIFT and PolyPhen2.3 A more detailed clinical inves-
tigation of this mutation has recently been published.24
Pro49 belongs to a fully hydrophobic nucleus
located between the ABD and CAM that is next to a
long flexible stretch of aa, Asn313-Pro325, connect-
ing the two structural modules. Substitution for ala-
nine does not disrupt the hydrophobicity of this area
and the mutation would not initially be expected to
exert a direct impact on Phe activation or tRNA
aminoacylation since it is located at a distance from
the active site. MD simulation demonstrates that
substitution of Pro49 for Ala changes the movement
of ABD along the trajectory towards the CAM.
During the first 20 ns of dynamic fluctuations the
system moves towards the “closed” form and
remained in this inactive conformation for an
extended time, thus causing impaired aminoacyla-
tion activity through a similar mechanism to that
observed for the Asp289Tyr mutant. The WT
HsmtPheRS and the Pro49Ala mutant stimulate
Phe-dependent ATP hydrolysis with nearly identical
specific activities (Table II). The kinetic study of
tRNAPhe charging revealed that due to a reduced
kcat there was only a 1.3-fold decrease in the kcat/Km
value (see Table I) suggesting that the P49A mutant
charges tRNAPhe in a way similar to the WT, which
correlates well with data in Table I.
Mutant His99Asp
Patient 2F is heterozygous (NM_006567.3) for
c.403C>G (3DN is His99Asp; see previous para-
graph).3,24 The previously published structures of
HsmtPheRS with tRNAPhe or Phe-AMP10,13 indicate
that His99 residue is located in the immediate vicin-
ity of the 3’-end of the tRNA. The 3’-end of tRNAPhe
is virtually clamped between the first intermediate,
Phe-AMP, and the Leu94-Gly105 fragment of the
CAM. The His99 side chain is exposed towards the
3’-end of the tRNA and since, the tRNA molecule is
negatively charged,20,25 the appearance of Asp99
instead of His99 may result in local destabilization
of the whole complex: HmstPheRS•tRNAPhe•Phe-
AMP. One can hypothesize that substitution of the
positively charged His99 by the negatively charged
aspartic acid will result in repulsion of the acceptor
stem from its correct position, where the tRNA is
charged with its cognate aa. Analysis of the MD snap-
shots of the mutant demonstrated that Asp99 forms a
stable HB (3 A˚) with Ser101 [Fig. 5(C)] that exists
65% of the entire travel time on the MD trajectory,
thereby stabilizing this new conformation. The Side
chain of a negatively charged Asp99 in mutant gener-
ates additional repulsion from tRNAPhe (also nega-
tively charged) on its pathway to the binding site. The
MD snapshots demonstrate that HB between the
amino group of Phe-substrate and Ser119, essential for
Phe-AMP formation, occurs less frequently as com-
pared to WT HsmtPheRS, thus explaining the signifi-
cant reduction in the aminoacylation activity (Table I).
A 40-fold reduction in the kcat/Km for His99Asp
variant results from a combined increased Km value
for Phe and a decreased kcat value and led to a 2.6-fold
reduction in the rate of ATP consumption (Table II).
Notably, the impact of the His99Asp mutation on Phe
activation (Fig. 3, Table I) does not correlate with the
impact on the catalytic efficiency of tRNAPhe. Substi-
tution of His for Asp impairs the aa activation step to
a lesser extent than the transfer step of Phe from
Phe-AMP to tRNAPhe (Tables I and II). The activity of
His99Asp mutant presented by Walker et al.24 was
not detected in aminoacylation reaction due to low
enzyme concentration used in experiments. We were
able to detect this activity only at very high enzyme
concentration. Data for activation reactions correlate
well with results presented in Ref. 22.
Mutant Arg387Gln
Patient 4M (Supporting Information Table S1) is a
4-year-old boy who presented with non-specific
developmental delay and hypotonia and was found
to have two heterozygous changes (c.737C>T
(p.Thr246Met; 3DN is Thr210Met) and c.1268G>A
(p. Arg423Gln; 3DN is Arg387Gln)) to the human
FARS2 (NM_006567.3) gene. SIFT and PolyPhen2
predicted Arg387Gln to be deleterious, but made a
discordant prediction regarding the pathogenicity for
Thr210Met.3
Arg387 is located in the ABD, is exposed to solu-
tion and the crystal structure of HsmtPheRS in com-
plex with tRNAPhe indicates that Arg387 has no
direct or indirect contacts with bound tRNAPhe [Fig.
6(A)].13 The substitution of Arg387 for glutamine
breaks a salt bridge between Arg387 and Glu393.
The substituted Gln387, however, also has a
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propensity to form HB since the amide group can
accept and donate a hydrogen atom. Thus, Gln387
and Glu393 may continue to maintain the HB and
support conformation of the Tyr378-Ser385 loop and
helix. Comparing the dynamic behavior of WT
HsmtPheRS with that of the Arg387Gln mutant, we
could conclude that catalytic efficiencies for these
two variants appear to be similar and the kinetic
experiments showed only a 1.2-fold decrease in the
kcat/Km value due to a reduced kcat (Table I).
Mutant Arg383Cys
Two siblings who are compound heterozygotes for
the variants Arg383Cys and an intragenic deletion
have a comparatively moderate presentation among
the spectrum of FARS2 related phenotypes.4 Clinical
features in these siblings include truncal hypotonia,
global developmental delays, mild facial dysmorphia,
and variable lactic academia. Another patient with
the Arg383Cys mutation (compound heterozygous
His123Pro from the mother; Arg383Cys from the
father) is a 17-year-old girl (Patient 3F) who displayed
developmental delay, encephalopathy, elevated CSF
lactate and abnormal respiratory enzymes, consistent
with reported clinical features for FARS2 defects.
Arg383 is a shape-generating residue of ABD,
making HB with Glu358 [Fig. 6(B)] and the carbonyl
group of Tyr324 (acceptor). A given net of HB
contributes significantly to stabilizing the ABD fold
by cross-linking three b-strands that form the inner
platform of ABD. Substitution of Arg383 for cysteine
may partially disrupt a salt bridge between Arg383
and Glu358, however, this mutation will not have a
harmful effect on the anticodon recognition or aminoa-
cylation of tRNAPhe, and since protonated Glu358 can
form HB with Cys. The Arg383Cys mutation leads to
an approximately twofold reduction in the catalytic
efficiency (Table I) as the kcat/Km is reduced due to a
1.8-fold increase of Km and a 1.3-fold decrease of kcat.
Mutant Thr210Met
Patient 4M (Supporting Information Table S1) is a
4-year-old boy with two heterozygous variants to
the FARS2 gene c.737C>T (Thr210Met) and
c.1268G>A (Arg387Gln) (p.T246M in 3DN is
Thr210Met) who presented with nonspecific develop-
mental delay and hypotonia. SIFT and PolyPhen2
predicted Arg423Gln to be deleterious but made a
discordant prediction regarding the pathogenicity for
Thr210Met.3
Residue Thr210 is located within the CAM but has
no direct contacts with either tRNAPhe or the Phe-AMP
intermediate. The Thr210Met substitution would not a
priori be predicted to change the mutant HsmtPheRS
architecture or the ability for Phe-AMP complex forma-
tion. The dominant mode after 30 ns of MD simulation
showed that the relative position of CAM and ABD is
similar to that observed for the crystal structure of WT
HsmtPheRS complexed with tRNAPhe [Fig. 2(A)].
Replacement of Thr210 by Met enhances hydrophobic
interactions with Phe61, Tyr65, Phe74, and Trp274
and led to a 1.4-fold increase in the catalytic effi-
ciency of tRNAPhe charging, due to a 3.3-fold decrease
inKm value for tRNA
Phe (see Table I).
Discussion
Here, we present the in-depth analysis of changes in
the 3D structure and kinetic characteristics of
HsmtPheRS, induced by pathogenic mutations in
the FARS2. Analysis of high resolution crystal struc-
tures of WT HmstPheRS and those complexed with
different functional ligands enables to follow the
Figure 6. Structural and functional characterization of the
Arg387Gln and Arg383Cys mutants of HsmtPheRS. (A) Dia-
gram depicting HB formation between residues Arg387 and
Glu393, stabilizing the conformation of the ABD, and con-
necting basic structural elements (two strands) within the
ABD of WT HsmtPheRS. (B) Diagram showing HB formation
between aa residues of two adjacent strands of the ABD in
the WT HsmtPheRS. Arg383 is a shape-generating residue of
ABD, makes HB with Glu358 and the carbonyl group of
Tyr324 (acceptor).
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reaction pathway by which HsmtPheRS catalyzes
attachment of Phe to tRNAPhe. The positions of the
residues that are critically important for the arrange-
ment and binding of Phe, ATP, tRNA substrates, and
for enzyme activity were established.10,13,26,27 Data
on the WT HsmtPheRS and mutants derived from
kinetic experiments, X-ray crystallography and MD
simulations are indicative of direct relationship
between conformational changes in 3D structure and
kcat/Km values of tRNA
Phe aminoacylation and/or
specific activity in the ATP consumption.
The most deleterious effect on enzymatic activity
were caused by the His99Asp and Arg117Gly muta-
tions, which demonstrated a 40- to 50-fold decrease in
catalytic efficiency of aminoacylation. Furthermore
the kinetic assays revealed that the Arg117Gly muta-
tion also led to a 24-fold reduction in the rate of ATP
consumption, whereas the effect of the His99Asp sub-
stitution was more modest with only a 2.6-fold reduc-
tion (see Tables I and II). This information will be
used more extensively to determine any correlation
between the molecular pathogenesis and the clinical
manifestation. The expanding resources resulting
from exome and whole genome sequencing together
with increased characterization of proteins has con-
firmed the importance of pathogenic mutations in
mitochondrial aaRSs as the cause of many neurologi-
cal disorders. The crystal structures of mutant ver-
sions of HsmtPheRS, together with the kinetic data
and MD simulations that are presented here exem-
plify how mutations can affect the overall structure in
ways that would not be predicted from 3D structure
only.
It was inferred that the severity of the disease
and the specific tissue phenotypes that was caused
by the different site of mutations of the same gene
might depend on residual enzymatic activity or
structural instability (see Tables I and II). It is
worth mentioning that all of the reported enzyme
activities were detected via in vitro assays that might
have some slight difference in vivo. Future compre-
hensive documentation of the clinical course of mito-
chondrial disease arising from specific mutations in
the aaRSs together with detailed structural analyses
will facilitate a better understanding of the molecular
mechanism underlying the pathogenesis, which may
in turn have predictive therapeutic potential.
Materials and Methods
tRNA aminoacylation
Aminoacylation reactions were performed at 378C in
reaction mixtures containing 50 mM Tris-HCl (pH
8.5), 30 mM MgCl2, 5 mM 2-mercaptoethanol, 5 mM
ATP, 0.5–3 lM [14C/3H]-labeled L-Phe, and 0.5 to 3 lM
Escherichia coli tRNAPhe transcript. The enzyme con-
centration varied from 0.15 lM for the wild-type
HsmtPheRS to 1.5 lM for mutants. At the appropriate
time points aliquots (4 mL) were spotted onto What-
man filter paper impregnated with 5% TCA. The fil-
ters were then extensively washed with ice-cold 5%
TCA, and TCA-insoluble radioactivity was measured
by liquid scintillation counting. The kinetic parame-
ters were calculated by a nonlinear regression fit
of the data to a Michaelis-Menten equation. The
reported kcat and Km values represent the average of
at least two determinations with experimental errors
within 15 to 20% of the indicated values.
ATP Hydrolysis Assay
Formation of aminoacyl-adenylate was directly mea-
sured by means of thin-layer chromatography.28 The
reaction mixture contained 50 mM Tris-HCl (pH
8.0), 30 mM MgCl2, 5 mM 2-mercaptoethanol, 1 mM
L-phenylalanine, 30 lM [a-32P]ATP, and 10 U/mL of
inorganic pyrophosphatase. The reaction, performed
at 378C, was initiated by adding 150 to 300 nM
PheRS (wild-type or mutant). ATP, Phe-AMP, and
AMP (formed during hydrolysis of Phe-AMP) were
separated by TLC (on PEI cellulose plates, Merck)
developed in a mixture of acetic acid, 1M ammonium
acetate, and water (5:10:85, v/v). The radioactivity of
spots was quantified by PhosphorImaging.
MD Simulation
The MD simulations of WT enzyme and the mutants
variants were conducted using GROMACS29 version
4.5.5. The multistep simulation protocol includes the
following stages. The Steepest Descent technique
(1000 steps) has been applied in a vacuum of the
mutated residues only, while keeping other atoms
restrained at their initial positions.
Water molecules were modeled as single point
charges (SPCs). Minimized structures were placed
at the center of a SPC water box. The total electric
charge of each protein-water system was neutralized
by sodium counter ions added to the system. The
energy of the solvated structures was then mini-
mized by using the steepest descent method (5000
steps) followed by conjugate gradient minimization
(10,000 steps). To achieve better relaxation for initial
configurations, a 100 ps MD simulation was per-
formed at constant pressure and temperature T
(300 K). The positions of protein nonhydrogen atoms
were restrained by a force constant of 1000
kJ mol21 A˚21. Bond lengths were restrained using
the LINCS algorithm30 applied with the 2 fs integra-
tion step, and the neighbor list for calculation of
nonbonded interactions was updated every five time
steps. Periodic boundary conditions were used, and
electrostatic interactions were calculated by using
the PME method31 with a short-range cutoff of
1.0 nm. For the Lennard–Jones interactions, a cutoff
value of 1.0 nm was used.
Trajectories (30–100 ns for each mutant) were
sampled at a constant pressure (1 bar) and
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temperature (300 K) using the Berendsen thermal
bath.29 A convergence and reproducibility of
mutant’s internal motion has been tested on trajec-
tories applying principal component analysis.32
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